Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

RISK OF SARCOPENIA IN RHEUMATOID ARTHRITIS PATIENTS (CROSBI ID 695218)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Vlak, Tonko RISK OF SARCOPENIA IN RHEUMATOID ARTHRITIS PATIENTS. London : Delhi: Springer Science+Business Media, 2018. str. 146-147 doi: 10.1007/s00198-018-4439-3

Podaci o odgovornosti

Vlak, Tonko

engleski

RISK OF SARCOPENIA IN RHEUMATOID ARTHRITIS PATIENTS

Objective:Rheumatoid arthritis is most frequently associatedwith development of sarcopenia among chronic inflammatorydisease group. Risk of adverse outcomes, such as physicaldisability, poor quality of life and higher mortality rates, inrheumatoid arthritis is increasing with the development ofsarcopenia. Therefore, we performed systematic literaturesearch to provide closer look in causal factors and risks fordevelopment of sarcopenia.Methods:A systematic literature search was carried out inMEDLINE ; Cochrane Library, PEDro and ACR/EULARmeeting abstracts.Results:Although the exact mechanisms for sarcopenia de-velopment in rheumatoid arthritis still remains to be elucidat-ed, several factor have been proposed such as increased pro-duction of pro-inflammatory cytokines, mainly tumor necrosisfactor-alpha and interleukin-1 beta, hormonal changes, oxida-tive damage, reduced protein synthesis in myocytes, insulinresistance, inadequate protein ingestion, physical activity lim-itation and pain. Furthermore, it is shown that somereumathoid arthritis associated disease and treatment charac-teristics can also contribute to development of sarcopenia suchas: increasing joint deformity, self-reported disability scores, C-reactive protein levels, rheumatoid factor seropositivity, anda lack of current treatment with disease-modifying antirheu-matic drugs. Sex and age differences should also be taken in toaccount when considering body composition phenotypes ofrheumatoid arthritis. The good news is that most of abovementioned factors could be alleviated but in order to start withthe treatment of sarcopenia we have to be aware of high prev-alence of sarcopenia among rheumatoid arthritis patients andimprove clinical detection tools.Conclusion:Risk of sarcopenia development in rheumatoidarthritis is rather high and can have devastating consequenceson quality of life, morbidity and mortality. In the managementS146Osteoporos Int (2018) 29 (Suppl 1):S109–S147 of rheumatoid arthritis patients, we should consider preven-tion and treatment of sarcopenia as one of main strategies.

Rheumatic Arthritis ; Sarcopenia

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

146-147.

2018.

objavljeno

10.1007/s00198-018-4439-3

Podaci o matičnoj publikaciji

London : Delhi: Springer Science+Business Media

0937-941X

Podaci o skupu

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018)

predavanje

19.04.2018-22.04.2018

Kraków, Poljska

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost